pp-050 Oral suspension

For pediatric attention-deficit/hyperactivity disorder (ADHD); also designed with a profile expected to benefit patients with autism spectrum disorder (ASD) who often have overlapping ADHD symptoms and difficulty with solid oral dosage forms. Phase 2 clinical development. Extended-release oral suspension formulation of a known ADHD therapeutic class. Designed to provide sustained symptom control throughout the day via extended-release delivery, improving adherence and reducing symptom rebound common with immediate-release ADHD medications. Route / form: Once-daily oral suspension (extended-release). Differentiation: Child-friendly liquid formulation for patients who cannot swallow tablets; smoother all-day coverage; expected applicability for children with ASD who may have dosing, sensory, or adherence challenges.